Using Ganciclovir to Prevent Cytomegalovirus Reactivation in Patients with Severe Respiratory Issues
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis
['FUNDING_OTHER'] · FRED HUTCHINSON CANCER CENTER · NIH-10916408
This study is looking at whether the antiviral medication ganciclovir can help prevent the reactivation of cytomegalovirus (CMV) in adults with severe respiratory failure caused by sepsis, to see if it can improve their recovery and reduce the time they spend on a ventilator and in the ICU.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10916408 on ClinicalTrials.gov |
What this research studies
This research investigates the use of ganciclovir, an antiviral medication, to prevent the reactivation of cytomegalovirus (CMV) in patients suffering from acute respiratory failure due to sepsis. CMV can reactivate during critical illness, leading to worse outcomes, and this study aims to determine if ganciclovir can effectively suppress this reactivation. The approach involves administering ganciclovir to CMV seropositive adults and monitoring their clinical outcomes, including the duration of mechanical ventilation and ICU stay. The research builds on previous findings that suggest ganciclovir may improve recovery in these patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are CMV seropositive and experiencing acute respiratory failure due to sepsis.
Not a fit: Patients who are not CMV seropositive or those with other underlying conditions that severely compromise their immune system may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved recovery rates and reduced hospital stays for patients with acute respiratory failure and sepsis.
How similar studies have performed: Previous studies have shown promising results with ganciclovir in similar patient populations, indicating a potential for significant clinical improvement.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BOECKH, MICHAEL J — FRED HUTCHINSON CANCER CENTER
- Study coordinator: BOECKH, MICHAEL J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.